Adial Pharmaceuticals (ADIL) Competitors $1.01 +0.01 (+1.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ADIL vs. BIVI, BGXX, GLYC, RNXT, IBIO, ATHA, TPST, PIRS, SPRB, and UBXShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include BioVie (BIVI), Bright Green (BGXX), GlycoMimetics (GLYC), RenovoRx (RNXT), iBio (IBIO), Athira Pharma (ATHA), Tempest Therapeutics (TPST), Pieris Pharmaceuticals (PIRS), Spruce Biosciences (SPRB), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. BioVie Bright Green GlycoMimetics RenovoRx iBio Athira Pharma Tempest Therapeutics Pieris Pharmaceuticals Spruce Biosciences Unity Biotechnology Adial Pharmaceuticals (NASDAQ:ADIL) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community believe in ADIL or BIVI? Adial Pharmaceuticals received 91 more outperform votes than BioVie when rated by MarketBeat users. However, 65.38% of users gave BioVie an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdial PharmaceuticalsOutperform Votes10858.06% Underperform Votes7841.94% BioVieOutperform Votes1765.38% Underperform Votes934.62% Which has higher valuation and earnings, ADIL or BIVI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$5.12MN/AN/ABioVieN/AN/A-$32.12M-$13.70-0.20 Does the media prefer ADIL or BIVI? In the previous week, BioVie had 6 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 7 mentions for BioVie and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.98 beat BioVie's score of 0.42 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in ADIL or BIVI? 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 5.2% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, ADIL or BIVI? Adial Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Do analysts prefer ADIL or BIVI? BioVie has a consensus price target of $4.00, indicating a potential upside of 44.40%. Given BioVie's higher probable upside, analysts clearly believe BioVie is more favorable than Adial Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABioVie 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is ADIL or BIVI more profitable? Adial Pharmaceuticals' return on equity of -183.64% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -183.64% -160.59% BioVie N/A -259.71%-125.68% SummaryAdial Pharmaceuticals beats BioVie on 7 of the 12 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.47M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.415.324.645.01Net Income-$5.12M$153.56M$119.13M$225.46M7 Day Performance-8.18%0.12%0.78%0.37%1 Month Performance6.26%15.23%5.65%3.57%1 Year Performance-57.02%41.16%36.90%29.42% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals1.4049 of 5 stars$1.01+1.0%N/A-53.7%$6.47MN/A0.0020BIVIBioVie2.5596 of 5 stars$2.77+1.1%$4.00+44.4%-39.8%$25.84MN/A-0.2010Gap UpBGXXBright GreenN/A$0.13-7.1%N/A-63.5%$24.85MN/A-2.172Gap DownGLYCGlycoMimetics4.3859 of 5 stars$0.38-5.0%$10.00+2,513.7%-69.6%$24.67M$10,000.00-0.6650Analyst ForecastOptions VolumeNews CoverageRNXTRenovoRx1.6731 of 5 stars$1.02+2.0%$6.13+500.5%-3.8%$24.47MN/A-1.706Positive NewsIBIOiBio1.0468 of 5 stars$2.67+3.1%$4.30+61.0%N/A$24.40M$225,000.000.00100ATHAAthira Pharma2.5581 of 5 stars$0.61+42.3%$13.83+2,183.1%-65.4%$23.29MN/A-0.2040Gap UpHigh Trading VolumeTPSTTempest Therapeutics2.245 of 5 stars$0.91-1.1%$20.75+2,181.7%-75.4%$23.07MN/A-0.5720PIRSPieris Pharmaceuticals2.3762 of 5 stars$17.30+0.3%N/A-14.4%$22.77M$42.81M-0.92140Gap DownSPRBSpruce Biosciences3.0101 of 5 stars$0.55+3.8%$5.00+812.1%-51.1%$22.64M$10.09M-0.5320Gap DownUBXUnity Biotechnology3.9281 of 5 stars$1.31-3.7%$6.67+408.9%-29.2%$22.07M$240,000.00-0.6660Positive News Related Companies and Tools Related Companies BioVie Alternatives Bright Green Alternatives GlycoMimetics Alternatives RenovoRx Alternatives iBio Alternatives Athira Pharma Alternatives Tempest Therapeutics Alternatives Pieris Pharmaceuticals Alternatives Spruce Biosciences Alternatives Unity Biotechnology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADIL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
